The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines.
Open accessAbstract
Synthetic peptide analogues of sequences in the HER-2 protooncogene (HER-2) were selected based on the presence of HLA-A2.1 anchor motifs to identify the epitopes on HER-2 recognized by ovarian tumor-reactive CTL. 19 synthetic peptides were evaluated for recognition by four HLA-A2 ovarian-specific cytotoxic T lymphocyte (CTL) lines obtained from leukocytes associated with ovarian tumors. The nonapeptide E75 (HER-2, 369-377:KIFGSLAFL) was efficient in sensitizing T2 cells for lysis by all four CTL lines. This peptide was specifically recognized by cloned CD8+ CTL isolated from one of the ovarian-specific CTL lines. E75-pulsed T2 cells inhibited lysis by the same CTL clone of both an HLA-A2+ HER-2high ovarian tumor and a HER-2high cloned ovarian tumor line transfected with HLA-A2, suggesting that this or a structurally similar epitope may be specifically recognized by these CTL on ovarian tumors. Several other HER-2 peptides were recognized preferentially by one or two CTL lines, suggesting that both common and private HER-2 epitopes may be immunogenic in patients with ovarian tumors. Since HER-2 is a self-antigen, these peptides may be useful for understanding mechanisms of tumor recognition by T cells, immunological tolerance to tumor, and structural characterization of tumor antigens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules
Falk, K., Rötzschke, O., Stevanovié, S., Jung, G., & Rammensee, H.-G. (1991) · Nature · doi:10.1038/351290a0 · Cited by 2,411
Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor
Yamamoto, T., Ikawa, S., Akiyama, T., Semba, K., Nomura, N., Miyajima, N., Saito, T., & Toyoshima, K. (1986) · Nature · doi:10.1038/319230a0 · Cited by 1,204
Characterization of Peptides Bound to the Class I MHC Molecule HLA-A2.1 by Mass Spectrometry
Hunt, D. F., Henderson, R. A., Shabanowitz, J., Sakaguchi, K., Michel, H., Sevilir, N., Cox, A. L., Appella, E., & Engelhard, V. H. (1992) · Science · doi:10.1126/science.1546328 · Cited by 1,198
Kawakami, Y., Eliyahu, S., Delgado, C. H., Robbins, P. F., Sakaguchi, K., Appella, E., Yannelli, J. R., Adema, G. J., Miki, T., & Rosenberg, S. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.14.6458 · Cited by 914
Kawakami, Y., Eliyahu, S., Sakaguchi, K., Robbins, P. F., Rivoltini, L., Yannelli, J. R., Appella, E., & Rosenberg, S. A. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.1.347 · Cited by 862
Identification of a Peptide Recognized by Five Melanoma-Specific Human Cytotoxic T Cell Lines
Cox, A. L., Skipper, J., Chen, Y., Henderson, R. A., Darrow, T. L., Shabanowitz, J., Engelhard, V. H., Hunt, D. F., & Slingluff, C. L. (1994) · Science · doi:10.1126/science.7513441 · Cited by 824
Gaugler, B., Van den Eynde, B., van der Bruggen, P., Romero, P., Gaforio, J. J., De Plaen, E., Lethé, B., Brasseur, F., & Boon, T. (1994) · The Journal of experimental medicine · doi:10.1084/jem.179.3.921 · Cited by 762
Madden, D. (1993) · Cell · doi:10.1016/0092-8674(93)90490-h · Cited by 675
Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules
Ruppert, J., Sidney, J., Celis, E., Kubo, R. T., Grey, H. M., & Sette, A. (1993) · Cell · doi:10.1016/0092-8674(93)90472-3 · Cited by 628
Kraus, M. H., Popescu, N. C., Amsbaugh, S. C., & King, C. R. (1987) · The EMBO Journal · doi:10.1002/j.1460-2075.1987.tb04797.x · Cited by 617
Cited by
Marincola, F. M., Jaffee, E. M., Hicklin, D. J., & Ferrone, S. (1999) · Advances in Immunology · doi:10.1016/s0065-2776(08)60911-6 · Cited by 1,174
Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy
Coulie, P. G., Van den Eynde, B. J., van der Bruggen, P., & Boon, T. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3670 · Cited by 1,138
Cold Tumors: A Therapeutic Challenge for Immunotherapy
Bonaventura, P., Shekarian, T., Alcazer, V., Valladeau-Guilemond, J., Valsesia-Wittmann, S., Amigorena, S., Caux, C., & Depil, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00168 · Cited by 1,108
A listing of human tumor antigens recognized by T cells
Renkvist, N., Castelli, C., Robbins, P. F., & Parmiani, G. (2001) · Cancer Immunology, Immunotherapy · doi:10.1007/s002620000169 · Cited by 694
Van den Eynde, B. J., & van der Bruggen, P. (1997) · Current Opinion in Immunology · doi:10.1016/s0952-7915(97)80050-7 · Cited by 623
Dynamics and specificities of T cells in cancer immunotherapy
Oliveira, G., & Wu, C. J. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00560-y · Cited by 616
Peptide-Based Vaccines: Current Progress and Future Challenges
Malonis, R. J., Lai, J. R., & Vergnolle, O. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00472 · Cited by 602
Brossart, P., Wirths, S., Stuhler, G., Reichardt, V. L., Kanz, L., & Brugger, W. (2000) · Blood · doi:10.1182/blood.v96.9.3102 · Cited by 552
Biochemical and Clinical Implications of the ErbB/HER Signaling Network of Growth Factor Receptors
(1999) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60784-8 · Cited by 540
Tumor antigens recognized by T cells
Boon, T., Coulie, P. G., & Van den Eynde, B. (1997) · Immunology Today · doi:10.1016/s0167-5699(97)80020-5 · Cited by 537
Restifo, N. P., Marincola, F. M., Kawakami, Y., Taubenberger, J., Yannelli, J. R., & Rosenberg, S. A. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.2.100 · Cited by 533
A listing of human tumor antigens recognized by T cells: March 2004 update
Novellino, L., Castelli, C., & Parmiani, G. (2005) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-004-0560-6 · Cited by 466
Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors
Leko, V., & Rosenberg, S. A. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.07.013 · Cited by 449
“, HER2 in ovarian and breast cancer (Fisk et al., 1995) and carcinoembryonic antigen (CEA) in a variety of epithelial cancers (Parkhurst et al.”
BackgroundKnutson, K. L., Schiffman, K., & Disis, M. L. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11752 · Cited by 439
Recent Advances in the Treatment of Breast Cancer
Tong, C. W. S., Wu, M., Cho, W. C. S., & To, K. K. W. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00227 · Cited by 399
Disis, M. L., Pupa, S. M., Gralow, J. R., Dittadi, R., Menard, S., & Cheever, M. A. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.11.3363 · Cited by 345
Immune Reconstitution and Immunotherapy After Autologous Hematopoietic Stem Cell Transplantation
Guillaume, T., Rubinstein, D. B., & Symann, M. (1998) · Blood · doi:10.1182/blood.v92.5.1471 · Cited by 323
Serological identification of human tumor antigens
Sahin, U., Türeci, Ö., & Pfreundschuh, M. (1997) · Current Opinion in Immunology · doi:10.1016/s0952-7915(97)80053-2 · Cited by 315
Role of HER2 gene overexpression in breast carcinoma
M�nard, S., Tagliabue, E., Campiglio, M., & Pupa, S. M. (2000) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(200002)182:2<150::aid-jcp3>3.0.co;2-e · Cited by 303
Human tumor antigens for cancer vaccine development
Wang, R., & Rosenberg, S. A. (1999) · Immunological Reviews · doi:10.1111/j.1600-065x.1999.tb01331.x · Cited by 296
Czerniecki, B. J., Koski, G. K., Koldovsky, U., Xu, S., Cohen, P. A., Mick, R., Nisenbaum, H., Pasha, T., Xu, M., Fox, K. R., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4038 · Cited by 266
Feuerer, M., Beckhove, P., Bai, L., Solomayer, E.-F., Bastert, G., Diel, I. J., Pedain, C., Oberniedermayr, M., Schirrmacher, V., & Umansky, V. (2001) · Nature Medicine · doi:10.1038/86523 · Cited by 263
Peptides for Vaccine Development
Hamley, I. W. (2022) · ACS Applied Bio Materials · doi:10.1021/acsabm.1c01238 · Cited by 104
Qi, L., Rojas, J.-M., & Ostrand-Rosenberg, S. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.10.5451 · Cited by 60
Recent advances in the treatment of epithelial ovarian cancer
Harries, M., & Kaye, S. B. (2001) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.10.9.1715 · Cited by 54
“The proteins from which these epitopes are derived include MUC-1 and HER-2/neu [93,94].”
Background
Metadata
- Authors
- Fisk, B., Blevins, T. L., Wharton, J. T., & Ioannides, C. G.
- Venue
- The Journal of experimental medicine
- Publisher
- Rockefeller University Press
- Published
- 1995-06-01
- Volume
- 181
- Issue
- 6
- Pages
- 2109-2117
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2145136557
- Cited by
- 543
- References
- 23
- FWCI
- 8.04
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.